News & Updates
Showing Pharmacy articles
Showing

Antidepressant nonresponders may benefit from rTMS
Repetitive transcranial magnetic stimulation (rTMS) demonstrates greater reduction in depressive symptoms than switching of antidepressant medications in patients with moderately treatment-resistant depression, reveals a study.
Antidepressant nonresponders may benefit from rTMS
10 Sep 2024
Ustekinumab biosimilar SB17 boasts similar efficacy, safety in psoriasis
SB17, a proposed ustekinumab (UST) biosimilar, demonstrates comparable efficacy, safety, and pharmacokinetics (PK) to the reference drug, as well as lower immunogenicity up to week 28, among individuals suffering from moderate-to-severe psoriasis, according to a study.
Ustekinumab biosimilar SB17 boasts similar efficacy, safety in psoriasis
10 Sep 2024
Four-drug pill beats three separate meds in difficult-to-treat hypertension
For individuals with difficult-to-treat hypertension who are struggling with three separate medications, a single pill that combines four blood pressure (BP)-lowering drugs may help with BP control, as shown in the phase III QUADRO trial.
Four-drug pill beats three separate meds in difficult-to-treat hypertension
07 Sep 2024
SGLT-2 inhibitors may prevent dementia in adults with T2D
Initiation of sodium-glucose cotransporter-2 (SGLT-2) inhibitors results in a 35-percent reduced risk of dementia compared with dipeptidyl peptidase-4 (DPP-4) inhibitors in individuals with type 2 diabetes (T2D) aged 40–69 years, according to a study. In addition, greater benefits are seen with longer treatment duration.
SGLT-2 inhibitors may prevent dementia in adults with T2D
07 Sep 2024
Tapinarof safe, efficacious for moderate-to-severe AD in children, adults
Treatment with tapinarof cream 1% once daily demonstrates significant efficacy with a favourable safety profile among adults and children with moderate-to-severe atopic dermatitis (AD), a study has shown.




